Nd:YAG Laser Hyaloidotomy for Premacular Hemorrhage in Diabetic Eyes

Premacular Subhyaloid hemorrhage is a sudden profound loss of vision in eyes with proliferative diabetic retinopathy (PDR). Pars plana vitrectomy is the treatment of choice for premacular hemorrhage in eyes with proliferative changes. Nd:YAG laser hyaloidotomy has been used to evacuate the premacular hemorrhage

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Proliferative Diabetic Retinopathy

Age range

21 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Eyes with premacular subhyaloid hemorrhage of more than 3 disc diameters, involving the fovea.
Eyes with proliferative diabetic retinopathy

Exclusion criteria

Dense media opacity (corneal/cataract)
Patients with bleeding tendency or on anti-coagulant drugs

Treatment and study plan

Nd:YAG laser Hyaloidotomy

Procedure

Using the YAG laser for opening the posterior hyaloid in eyes with premacular hemorrhage, and evacuating the entrapped hemorrhage

Primary outcomes

Visual acuity improvement

Time frame: 1 week

Testing VA after YAG laser

Sponsors and collaborators

Lead sponsor

Tanta University

Other

Registry information

Official study title

Evaluation of Nd:YAG Laser Hyaloidotomy for Management of Premacular Subhyaloid Hemorrhage in Eyes With Proliferative Diabetic Retinopathy

Important dates

Study start: 2015
Primary completion: 2020
Study completion: 2020
First posted: Feb 26, 2020
Registry last updated: Feb 26, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed